TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.66 USD
-0.05 (-2.92%)
Updated Sep 23, 2024 09:39 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for TherapeuticsMD, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 49 | 65 | 80 | 161 |
Receivables | 3 | 0 | 36 | 32 | 24 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 8 | 8 | 12 |
Other Current Assets | 4 | 6 | 11 | 8 | 11 |
Total Current Assets | 12 | 55 | 119 | 128 | 208 |
Net Property & Equipment | 0 | 0 | 1 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 18 | 20 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 7 | 40 | 41 | 44 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 43 | 90 | 169 | 182 | 266 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 2 | 20 | 21 | 19 |
Current Portion Long-Term Debt | 0 | 0 | 188 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 19 | 44 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 26 | 0 | 38 | 34 |
Total Current Liabilities | 7 | 47 | 253 | 59 | 53 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 238 | 195 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 2 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14 | 55 | 263 | 306 | 257 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 979 | 975 | 957 | 755 | 704 |
Retained Earnings | -950 | -939 | -1,051 | -879 | -695 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 35 | -94 | -124 | 9 |
Total Liabilities & Shareholder's Equity | 43 | 90 | 169 | 182 | 266 |
Total Common Equity | 29 | 35 | -94 | -124 | 9 |
Shares Outstanding | 10.50 | 9.40 | 8.40 | 6.00 | 5.40 |
Book Value Per Share | 2.79 | 3.74 | -11.15 | -20.67 | 1.70 |
Fiscal Year End for TherapeuticsMD, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 4 | 4 | 10 | 14 |
Receivables | 3 | 3 | 3 | 3 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 4 | 5 | 5 |
Total Current Assets | 12 | 12 | 12 | 17 | 20 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 17 | 18 | 18 | 19 | 20 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 6 | 6 | 7 | 7 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 40 | 42 | 43 | 50 | 54 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 3 | 7 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 4 | 4 | 7 | 1 |
Total Current Liabilities | 6 | 6 | 7 | 15 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 13 | 14 | 22 | 22 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 979 | 979 | 979 | 977 | 977 |
Retained Earnings | -951 | -950 | -950 | -949 | -945 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 28 | 29 | 29 | 28 | 31 |
Total Liabilities & Shareholder's Equity | 40 | 42 | 43 | 50 | 54 |
Total Common Equity | 28 | 29 | 29 | 28 | 31 |
Shares Outstanding | 11.50 | 11.50 | 10.50 | 10.50 | 10.10 |
Book Value Per Share | 2.41 | 2.49 | 2.79 | 2.67 | 3.09 |